6T8V

Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole

これはPDB形式変換不可エントリーです。

6T8V の概要

• エントリーDOI: 10.2210/pdb6t8v/pdb
• 分子名称: Complement factor B, SULFATE ION, 4-[(2~{S})-1-[(5,7-dimethyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid, ... (5 entities in total)
• 機能のキーワード: complement immune, inhibitor, hydrolase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 67247.83

構造登録者

Mainolfi, N.,Ehara, T.,Karki, R.G.,Anderson, K.,Mac Sweeney, A.,Wiesmann, C.,Adams, C.,Mainolfi, N.,Liao, S.-M.,Argikar, U.A.,Jendza, K.,Zhang, C.,Powers, J.,Klosowski, D.W.,Crowley, M.,Kawanami, T.,Ding, J.,April, M.,Forster, C.,Serrano-Wu, M.,Capparelli, M.,Ramqaj, R.,Solovay, C.,Cumin, F.,Smith, T.M.,Ferrara, L.,Lee, W.,Long, D.,Prentiss, M.,De Erkenez, A.,Yang, L.,Fang, L.,Sellner, H.,Sirockin, F.,Valeur, E.,Erbel, P.,Ramage, P.,Gerhartz, B.,Schubart, A.,Flohr, S.,Gradoux, N.,Feifel, R.,Vogg, B.,Wiesmann, C.,Maibaum, J.,Eder, J.,Sedrani, R.,Harrison, R.A.,Mogi, M.,Jaffee, B.D.,Adams, C.M. (登録日: 2019-10-25, 公開日: 2020-03-04, 最終更新日: 2024-11-13)

主引用文献

Mainolfi, N.,Ehara, T.,Karki, R.G.,Anderson, K.,Mac Sweeney, A.,Liao, S.M.,Argikar, U.A.,Jendza, K.,Zhang, C.,Powers, J.,Klosowski, D.W.,Crowley, M.,Kawanami, T.,Ding, J.,April, M.,Forster, C.,Serrano-Wu, M.,Capparelli, M.,Ramqaj, R.,Solovay, C.,Cumin, F.,Smith, T.M.,Ferrara, L.,Lee, W.,Long, D.,Prentiss, M.,De Erkenez, A.,Yang, L.,Liu, F.,Sellner, H.,Sirockin, F.,Valeur, E.,Erbel, P.,Ostermeier, D.,Ramage, P.,Gerhartz, B.,Schubart, A.,Flohr, S.,Gradoux, N.,Feifel, R.,Vogg, B.,Wiesmann, C.,Maibaum, J.,Eder, J.,Sedrani, R.,Harrison, R.A.,Mogi, M.,Jaffee, B.D.,Adams, C.M.
Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
J.Med.Chem., 63:5697-5722, 2020

PubMed Abstract: The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (), which is currently being evaluated clinically in several diverse AP mediated indications.

PubMed: 32073845
DOI: 10.1021/acs.jmedchem.9b01870

実験手法

X-RAY DIFFRACTION (2.29 Å)